A Brief History of the GMPs for Pharmaceuticals

Pharmaceutical Technology North America

Volumn 25, Issue 7, 2001, Pages 44-52

  Immel, Barbara K ^a  

^a Immel Resources   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0347751151     PISSN: 15342131     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. S. Ward, "Summary of The Jungle by Upton Sinclair," SparkNotes Online Study Guide (TheSpark.com Inc., Cambridge, MA, 1999), www.sparknotes.com/guides/jungle.
2. Requirements of Laws and Regulations Enforced by the U.S. Food and Drug Administration (FDA, Rockville, MD, revised 1997), www.fda.gov/opacom/morechoices/smallbusiness/blubook.htm.
3. Office of Women's Health, FDA Milestones in Women's Health: Looking Back as We Move into the New Millennium (FDA, Rockville, MD, 2000), www.fda.gov/womens/milesbro.html.
4. FDA History: FDA Commissioners and Their Predecessors (FDA, Rockville, MD, rev. 6 April 2000), www.fda.gov/opacom/morechoices/comml.html.
5. R. Roberts, Safety Assessment in Pediatrics (Center for Drug Evaluation and Research, FDA, 8 July 1999), www.fda.gov/cder/present/dia-699/sa-dia99/index.htm.
6. Center for Drug Evaluation and Research, Time Line: Chronology of Drug Regulation in the United States (FDA, Rockville, MD), www.fda.gov/cder/about/history/time1.htm.
7. "Milestones in US Food and Drug Law History," in FDA Backgrounder: Current and Useful Information from the Food and Drug Administration (FDA, Rockville, MD, August 1995), www.fda.gov/opacom/backgrounders/miles.html.
8. "Jonas Salk, MD - Biography" (American Academy of Achievement, 2000), www.achievement.org/autodoc/halls/sci and Webster's New Collegiate Dictionary (G&C Merriam Company, Springfield, MA, 1975).
9. I.B. Stehlin, "Assessing Risks with Polio Vaccines," FDA Consumer 29 (10) (December 1995), www.fda.gov/fdac/features/095_vacc.html.
10. Code of Federal Regulations, Title 21, Food and Drugs, "Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs," Part 210-211 (US Printing Office, Washington, DC, revised April 2000).
11. Code of Federal Regulations, Title 21, Food and Drugs, "Medical Devices: Current Good Manufacturing Practices (CGMP) Final Rule," Part 820 (US Printing Office, Washington, DC, revised April 1999).
12. Code of Federal Regulations, Title 21, Food and Drugs, "General: Good Laboratory Practice for Nonclinical Laboratory Studies," Part 58 (US Printing Office, Washington, DC, revised April 2000).
13. T. Nordenberg, "Protecting Against Unwanted Pregnancy: A Guide to Contraceptive Choices," FDA Consumer 31 (3) (April 1997), www.fda.gov/fdac/features/1997/397_baby.html.
14. T. Nordenberg, "FDA and Medical Devices: After 20 Years, a Look Back, a Look Ahead," FDA Consumer 30 (10) (December 1996), www.fda.gov/fdac/features/096_mdev.html.
15. T. Kaplan, "The Tylenol Crisis: How Effective Public Relations Saved Johnson & Johnson" (Penn State University Personal Web Pages, PA, 1998), www.personal.psu.edu/users/w/x/wxk116/tylenol/crisis.html.
16. National Center for Drugs and Biologics, Guide to Inspection of Computerized Systems in Drug Processing (FDA, Rockville, MD, February 1983), www.fda.gov/ora/inspect_ref/igs/csd.html.
17. Center for Drug Evaluation and Research, Guideline on General Principles of Process Validation (FDA, Rockville, MD, May 1987), www.fda.gov/cder/guidance/pv.htm.
18. Center for Food Safety and Applied Nutrition, FDA Talk Paper: Impurities Confirmed in Dietary Supplement 5-Hydroxy-L-Tryptophan (FDA, Washington, DC, 31 August 1998).
19. Center for Biologics Evaluation and Research, Draft Guidance for Industry: Manufacturing, Processing, or Holding of Active Pharmaceutical Ingredients (FDA, Rockville, MD, March 1998), www.fda.gov/cber/gdlns/active.pdf.
20. International Conference on Harmonisation, "Guide for Industry: E6, Good Clinical Practice - Consolidated Guidance," Federal Register, 62 (90), 25691-25709 (9 May 1997), www.fda.gov/cder/guidance/959fnl.pdf.
21. Draft Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production, (FDA, Rockville, MD), September 1998, www.fda.gov/cder/guidance/1212dft.pdf.
22. T. Nordenberg, "Inside FDA: Barring People from the Drug Industry," FDA Consumer 31 (2), www.fda.gov/ora/compliance_ref/default.htm.
23. Office of Regulatory Affairs Compliance Reference: Debarment List (FDA, Rockville, MD), www.fda.gov/ora/compliance_ref/debar/default.htm.